JCH EMS SYSTEM MEDICATION LIST

| General principles | |
|---|------------------|
| Activated Charcoal | |
| Adenosine (Adenocard) | M-1.1 |
| Albuterol | M-1.2 |
| Aspirin | M-1.3 |
| Atropine | M-1.4 |
| Calcium Chloride | M-1.5 |
| 50% Dextrose | M-1.6 |
| Diazepam(Valium) | M-1.7 |
| Diphenhydramine (Benadryl | M-1.8 |
| Dopamine (Intropin) | M-1.9 |
| Epinephrine 1:1000 | M-1.10 |
| Epinephrine 1:10,000 | M-1.11 |
| Epi-pen | M-1.12 |
| Furosemide (Lasix) | M-1.12 M-1.13 |
| Glucagon | M-1.14 |
| Lidocaine (Xylocaine) | M-1.14 M-1.15 |
| Magnesium Sulfate | M-1.16 |
| Morphine | M-1.17 |
| Naloxone (Narcan) | M-1.18 |
| Nitroglycerin | M-1.19 |
| Oral Glucose Gel (Insta-Glucose, Glutose) | M-1.20 |
| Oxytocin (Pitocin) | M-1.21 |
| Phenergan | M-1.22 |
| Sodium Bicarbonate | M-1.23 |
| Verapamil | M-1.24 |
| Metoprolol Tartrate | M-1.25 |
| Plavix | M-1.26 |
| Versed (Midazolam) | M-1.27 |
| Norcuron | M-1.28 |
| Zofran | M-1.29 |
| Fentanyl Citrate () | M-1.30 |
| Fentanyl Citrate Pectal Diazepam (Valum) | |
| IV FLUIDS | M1.31 |
| 0.9% Sodium Chloride (Normal Saline) | M-2.1 |

Pharmacology

GENERAL PRINCIPLES

- 1. Known allergies must be assessed prior to administration of a medication.
- 2. Verify right patient, right drug, right dose, right route, right time of administration.
- 3. The maximum dose of any pediatric medication is equal to the adult dose.
- 4. A Broselow tape or similar device is highly encouraged when calculating pediatric drug dosages, particularly for the unstable child.
- 5. Any medications given IV should be inserted into the tubing port closest to the needle insertion site. Immediately following medication administration, a saline flush of 5-10 mL should be given.
- 6. IV fluids will be at keep open (TKO) rate (30ml/hr for adults, 20ml/hr for pediatrics) unless patient condition indicates a need for higher flow rates. A saline lock may be utilized on stable patients.
- 7. In the unstable patient, if IV access is delayed or cannot be achieved, IO administration of medications should be utilized only as a last resort when IV or IO access is not readily obtainable.
- 8. Endotracheal medications should be administered at twice the regular dose. No further dilution is required.
- 9. Naloxone, Atropine, and Epinephrine are approved for endotracheal administration.
- 10. An allergy to a medication or another of its class is a contra-indication for administration of a medication.

| ACTIVATED CHARCOAL | | |
|--------------------|--|--|
| CLASS | | |
| ACTION | Activated charcoal is useful in absorbing gases and toxins from mineral, bacterial, viral and plant sources. | |
| INDICATIONS | Selective poisonings | |
| CONTRAINDICATIONS | Inability to swallow safely/loss of gag reflex Gastrointestinal perforation or small bowel obstruction | |
| PRECAUTIONS | 8 | |
| SIDE EFFECTS | Diarrhea Vomiting Aspiration of activated charcoal results in very high morbidity and mortality | |
| ROUTE | Butter of the morality | |
| DOSE | Adult: 1 g/kg POPediatric: 1g/kg PO | |
| PEDIATRIC DOSE | a a state of the s | |
| ONSET | | |
| DURATION | | |
| STOCK | | |

| | ADENOGINE (ADENOGADD) |
|-------------------|---|
| CLASS | ADENOSINE (ADENOCARD) |
| ACTION | Antiarrhythmic; nucleoside |
| Merion | slows the heart rate by slowing conduction through the AV |
| | node. Blocks re-entry pathways in supraventricular tachycardias. |
| INDICATIONS | Narrow complex tech - 1' C |
| | Narrow complex tachycardias; Supraventricular tachycardias (SVT) |
| CONTRAINDICATIONS | Second or third degree heart block, sick sinus syndrome, |
| | hypersensitivity to the drug |
| PRECAUTIONS | Can produce bronchoconstriction in asthma patients. |
| SIDE EFFECTS | Side effects are usually brief due to the short half life of the drug. |
| | Conversion arrhythmias |
| | Facial flushing |
| | Headache |
| | Shortness of breath |
| | n Dizziness |
| | Lightheadedness |
| | ■ Nausea |
| | ■ Chest pain |
| ROUTE | Rapid IV bolus over 1-2 seconds via antecubital IV site. Follow |
| | each dose with 10 to 20 mL flush of normal saline and raise the |
| | arm. |
| DOSE | ■ Initial dose = 6 mg |
| | Second dose of 12 mg in 1-2 minutes if rhythm does not |
| | convert |
| | Repeat 12 mg dose again in 1-2 minutes if rhythm does not |
| PEDIATRIC DOSE | convert |
| FEDIATRIC DOSE | 0.1 mg/kg very rapidly at closest central IV injection site |
| | Repeat dose is 0.2 mg/kg |
| | Maximum single dose = 12 mg |
| | Utilize Broselow tape or pediatric weight based dosing chart to confirm dose. |
| | |
| ONSET | Reference policy PED-5 Immediate |
| DURATION | 1-2 minutes |
| STOCK | (5) 6 mg/2 mL vials |
| | (3) o mg/2 file viais |

| ALF | BUTEROL (PROVENTIL, VENTOLIN) |
|-------------------|--|
| CLASS | Beta-2 agonist; synthetic sympathomimetic |
| ACTION | Stimulates beta 2 receptor sites in the smooth muscle of the |
| | bronchial tree to reverse bronchospasm. |
| INDICATIONS | Asthma, emphysema, bronchospasm associated with other |
| | conditions, |
| CONTRAINDICATIONS | Known hypersensitivity to the drug |
| PRECAUTIONS | Could cause severe paradoxical bronchospasm with repeated |
| | excessive use. |
| SIDE EFFECTS | ■ Tachycardia |
| | Palpitations |
| | * Anxiety |
| | ■ Tremors |
| | Headache |
| | ■ Sweating |
| | ■ Bad taste |
| | ■ PVC's |
| | Hypotension |
| ROUTE | Inhalation via nebulizer |
| DOSE | 2.5 mg |
| PEDIATRIC DOSE | Per order of Medical Control |
| | Reference policy PED – 7.2 |
| ONSET | 5 to 15 minutes |
| DURATION | 2 to 3 hours |
| STOCK | (4) 2.5 mg/3 mL unit doses |
| | |

| ASPIRIN CHEWABLE | | |
|-------------------|---|--|
| CLASS | Anti-inflammatory; platelet aggregation inhibitor | |
| ACTION | Prevents formation of clots by blocking formation of thromboxane | |
| | A2 which causes platelets to aggregate and arteries to constrict. | |
| INDICATIONS | Acute coronary syndrome; acute MI; chest pain (non-traumatic) | |
| CONTRAINDICATIONS | Known hypersensitivity to the drug | |
| | ■ Bleeding disorders | |
| | Active ulcer disease | |
| | - Asthma | |
| PRECAUTIONS | None | |
| SIDE EFFECTS | Nausea/vomiting | |
| | ■ Heartburn | |
| | ■ GI bleeding | |
| | Increased bleeding time | |
| | Wheezing | |
| ROUTE | Oral – have the patient chew all four tablets and swallow | |
| DOSE | Four 81 mg chewable tablets | |
| PEDIATRIC DOSE | None | |
| ONSET | 30 to 60 minutes | |
| DURATION | 4 to 6 hours | |
| STOCK | (4) chewable tablets 81 mg each | |

| ATROPINE SULFATE | |
|-------------------|--|
| CLASS | Parasympathetic blocker; anti-cholinergic |
| ACTION | Increases the heart rate (positive chronotrope) by binding to muscarinic receptor sites to block the action of acetylcholine. Enhances both sinus node automaticity and atrioventricular conduction. |
| INDICATIONS | Symptomatic bradycardia Asystole Pulseless Electrical activity (PEA) with rate less than 60 Organophosphate poisoning |
| CONTRAINDICATIONS | Use with caution in high degree heart blocks with wide QRS Use with caution in the patient with MI as an increase in heart rate could increase cardiac workload |
| PRECAUTIONS | A dose less than 0.5 mg in the adult could result in paradoxical slowing of the heart rate. |
| SIDE EFFECTS | Tachycardia Hypertension Palpitations Headache Blurred vision Dilated pupils Dry mouth Confusion Drowsiness |
| ROUTE | ■ IV push ■ Endotracheal |
| DOSE | Symptomatic bradycardia: 0.5 mg every 5 minutes to maximum dose of 3 mg. Asystole/PEA: 1 mg every 3-5 minutes to maximum dose of 3 mg. Organophosphate poisoning: 2-5 mg IVP |
| PEDIATRIC DOSE | 0.02 mg/kg Minimum single dose is 0.1 mg. Maximum single dose 0.5 mg May repeat once Use Broselow tape or pediatric weight based dosing chart to confirm dose. Reference policy PED-3.2 |
| ONSET | 2 to 5 minutes |
| DURATION | 20 minutes |
| STOCK | (5) 1 mg/10 mL Abbojects |

| | CALCIUM CHLORIDE | |
|-------------------|--|--|
| CLASS | Calcium salt | |
| ACTION | Positive inotrope (increases the force of contraction) Increases myocardial automaticity | |
| INDICATIONS | Calcium channel blocker overdose Hypocalcemia Magnesium intoxication Hyperkalemia | |
| CONTRAINDICATIONS | Patients taking digitalis (Digoxin, lanoxin) | |
| PRECAUTIONS | Precipitates with sodium bicarbonate – flush the IV line before and after administration. | |
| SIDE EFFECTS | Extravasation (infiltration) can cause necrosis, sloughing of skin or abscess. Hypotension | |
| ROUTE | IV | |
| DOSE | 0.5 grams (500 mg) IV | |
| PEDIATRIC DOSE | Per Medical Control Utilize Broselow tape or pediatric weight based dosing chart to confirm dose | |
| ONSET | 5 to 15 minutes | |
| DURATION | Dose dependent (effects may last up to 4 hours) | |
| STOCK | (1) 10 mL Abboject (100 mg/mL) | |

| | DEXTROSE 50% | |
|-------------------|--|--|
| CLASS | Hyperglycemic agent; hypertonic agent | |
| ACTION | Supplies supplemental glucose to elevate the blood sugar. | |
| INDICATIONS | Hypoglycemia | |
| | Suspected hypoglycemia in coma of unknown origin | |
| CONTRAINDICATIONS | Do not administer to head injured patients unless they are | |
| | hypoglycemic | |
| PRECAUTIONS | Extravasation (infiltration) can cause pain, tissue necrosis | |
| SIDE EFFECTS | ■ Irritation to vein with pain and redness | |
| ROUTE | IV | |
| DOSE | 25 grams (50 mL) | |
| PEDIATRIC DOSE | (0.5-1.0 g/kg): | |
| | > 8yrs. D50% 1-2ml/kg IV/IO | |
| | ■ 1-8 yrs. D25% 2-4 ml/kg IV/IO | |
| | <1 yr. D12.5%* 4ml//kg IV/IO for infants | |
| | Utilize Broselow tape or pediatric weight based dosing | |
| | chart to confirm dose | |
| | ■ To make D12.5% dilute D25% 1:1 with sterile water | |
| | Reference policy PED-12.2 | |
| ONSET | 30 to 60 seconds | |
| DURATION | Depends upon the level of hypoglycemia | |
| STOCK | (2) 25 gram/50 mL Abbojects (50% solution) | |
| | (1) 2.5 gram/10 mL Abboject for children over 2 months (25% | |
| | solution) | |

| | DIAZEPAM (VALIUM) |
|-------------------|--|
| CLASS | Benzodiazepine |
| | Anticonvulsant; skeletal muscle relaxant, sedative-hypnotic |
| ACTION | Anticonvulsant properties due to enhancement of GABA-mediated |
| | presynaptic inhibition at the spinal level as well as in the brain stem |
| | reticular formation. CNS depressant. |
| INDICATIONS | Active seizures |
| | Sedation prior to synchronized cardioversion |
| | Sedation prior to transcutaneous pacing |
| | Acute anxiety |
| CONTRAINDICATIONS | History of hypersensitivity to the drug. |
| PRECAUTIONS | May precipitate if mixed with other drugs – always flush |
| | the IV line before and after administration. |
| | Elderly patients may experience adverse effects more |
| | quickly – administer the medication slowly. |
| | Monitor level of consciousness, BP, pulse and respiratory |
| | status closely |
| | Be prepared to manage the airway |
| SIDE EFFECTS | CNS depression; drowsiness |
| | Respiratory depression |
| | ■ Hypotension |
| | Phlebitis; venous thrombosis |
| ROUTE | IV (administer no faster than 1 mg/minute) |
| | IM (Onset of action 15-30 minutes) |
| | Rectal |
| DOSE | Seizures: 5-10 mg slow IV push at 1 mg/minute. Maximum |
| | dose of 10 mg. |
| | Sedation prior to electrical therapy: 5-10 mg slow IV push |
| | at 1 mg/minute. Maximum dose of 10 mg. |
| | Acute anxiety: 2-5 mg IM or slow IV push. |
| PEDIATRIC DOSE | For Seizures: 0.1-0.3 mg/kg slow IV push over 2-3 |
| | minutes. |
| | Less than age 5 maximum dose = 5 mg |
| | Over age 5 maximum dose 10 mg |
| | Utilize Broselow tape or pediatric weight based dosing |
| | chart to confirm dose. |
| | Reference policy PED-11.2 |
| ONSET | IV = less than 15 minutes |
| | IM = 15 to 30 minutes |
| DURATION | 3 hours |
| STOCK | (2) 10 mg/2 mL syringes |

| D | IPHENHYDRAMINE (BENADRYL) |
|-------------------|--|
| CLASS | Antihistamine |
| ACTION | Competes with histamine for H1 histamine receptor sites. |
| | ■ Anticholinergic |
| | ■ Antiemetic |
| INDICATIONS | ■ Allergic reaction; anaphylaxis |
| | Dystonic reaction due to phenothiazines (Ex: Phenergan) |
| | ■ Nausea/vomiting |
| CONTRAINDICATIONS | Known hypersensitivity to the drug |
| | Acute asthma attack |
| PRECAUTIONS | May cause drowsiness and sedation. |
| SIDE EFFECTS | CNS depression; drowsiness; confusion |
| | ■ Dizziness; vertigo |
| | Excitement especially in children |
| | ■ Tachycardia |
| | Palpitations |
| | ■ Ataxia |
| | ■ Dry mouth |
| | ■ Blurred vision |
| | ■ Headache |
| | Urine retention |
| ROUTE | ■ IV (Slow IVP at 25 mg/minute) |
| | ■ Deep IM |
| DOSE | 25-50 mg |
| PEDIATRIC DOSE | ■ 1-2 mg/kg |
| | Utilize Broselow tape or pediatric weight based dosing |
| | chart to confirm dose |
| | Reference policy PED-10.2 |
| ONSET | IV = 1 to 5 minutes |
| | IM = 15 minutes |
| DURATION | 3 to 4 hours |
| STOCK | (1) 50mg/mL injectable |

| | DOPAMINE (INTROPIN) |
|-------------------|---|
| CLASS | Vasopressor; Adrenergic; Catecholamine |
| ACTION | Acts on alpha and beta 1 receptor sites to vasoconstrict and |
| | increase heart rate. |
| | Positive chronotrope (increases heart rate) |
| | Positive inotrope (increases force of cardiac contraction |
| | Vasopressor at higher doses (increases BP) |
| INDICATIONS | Symptomatic bradycardia refractory to atropine |
| | Cardiogenic shock with hypotension |
| CONTRAINDICATIONS | Hypersensitivity to the drug |
| | Mypovolemic shock |
| | ■ Tachydysrhythmias |
| | Ventricular dysrhythmias (V-tach / V-fib) |
| PRECAUTIONS | Dopamine is not a substitute for fluid or blood volume |
| | deficits |
| | Extravasation (infiltration) can cause necrosis with tissue |
| | sloughing |
| | Monitor vital signs every 5 minutes during administration |
| | Monitor cardiac rhythm closely. |
| SIDE EFFECTS | ■ Tachycardia |
| | Ectopic beats |
| | ■ Angina |
| | ≠ Palpitations |
| | Headache |
| | Nausea; vomiting |
| | Hypertension |
| ROUTE | IV infusion (The infusion rate must be monitored precisely – |
| | preferred to use with an IV pump) |
| DOSE | Symptomatic bradycardia: 5-10 mcg/kg/minute |
| | Cardiogenic shock: 5-20 mcg/kg/minute |
| PEDIATRIC DOSE | Per Medical Control 5-20 mcg/kg/minute infusion |
| | Utilize Broselow tape or pediatric weight based dosing |
| | chart to confirm dose |
| | Reference policy PED-9.2 |
| ONSET | 5 minutes |
| DURATION | 5 to 10 minutes |
| STOCK | (1) 1600 mcg/mL premix solution (800 mg/500 mL) |

| EPINEPHRINE 1:1000 SOLUTION | |
|-----------------------------|--|
| CLASS | Sympathomimetic; Catecholamine; bronchodilator |
| ACTION | Beta-2 receptor agonist promotes bronchodilation |
| | Beta-1 receptor agonist = positive chronotrope(increases |
| | heart rate); positive inotrope (increases force of cardiac |
| | contraction) |
| INDICATIONS | Allergic reaction |
| | Anaphylaxis |
| | Asthma |
| | Exacerbation of some forms of COPD |
| CONTRAINDICATIONS | Patients with underlying cardiovascular disease |
| | Hypertension |
| | Pregnancy (safety in pregnancy and lactation not |
| | established) |
| | Patients with tachydysrhythmias |
| PRECAUTIONS | Protect from light |
| | Monitor vital signs every 5 minutes |
| | Monitor cardiac rhythm closely |
| SIDE EFFECTS | ■ Tachycardia |
| | Palpitations |
| | Anxiety; restlessness |
| | ■ Tremors |
| | Headache |
| ROUTE | Subcutaneously |
| DOSE | 0.3 mg SQ |
| PEDIATRIC DOSE | ■ 0.01 mg/kg up to 0.3 mg |
| | Utilize Broselow tape or pediatric weight based dosing |
| | chart to confirm dose |
| | Reference policy PED-10.2 |
| ONSET | 5 to 10 minutes |
| DURATION | 20 minutes |
| STOCK | (3) 1 mg/mL ampules |
| | (1) 30 mL multidose vial (1 mg/mL) |

| | EPINEPHRINE 1:10,000 |
|-------------------|--|
| CLASS | Catecholamine; cardiac stimulant |
| ACTION | ■ Beta 1 and beta 2 adrenergic effects |
| | Positive chronotrope (increases heart rate) |
| | Positive inotrope (increases force of cardiac contraction |
| INDICATIONS | Cardiac arrest with ventricular fibrillation, pulseless |
| | ventricular tachycardia, asystole, pulseless electrical |
| | activity (PEA) |
| | Anaphylaxis |
| CONTRAINDICATIONS | None when used in an emergency situation such as cardiac arrest |
| PRECAUTIONS | ■ Protect from light |
| | Can be deactivated by alkaline solutions – flush the IV line |
| | before and after administration |
| SIDE EFFECTS | Tachydysrhythmias |
| ROUTE | IV |
| | Endotracheal (ET) |
| DOSE | ■ Cardiac arrest: 1 mg every 3-5 minutes; ET dose is 2 – 2.5 |
| | mg |
| | ■ Anaphylaxis: 0.3-0.5 mg slow IVP |
| PEDIATRIC DOSE | ■ 0.01 mg/kg IV |
| | Utilize Broselow tape or pediatric weight based dosing |
| | chart to confirm dose |
| | ■ Reference policy PED-2.2 |
| ONSET | IV = immediate |
| DURATION | 3 to 5 minutes |
| STOCK | (6) 1 mg/10 mL Abbojects |

| EPI-PEN | |
|-------------------|--|
| CLASS | Catecholamine |
| ACTION | Produces bronchodilation |
| | Positive chronotrope (increases heart rate) |
| | Positive inotrope (increases force of cardiac contraction) |
| INDICATIONS | Anaphylaxis |
| CONTRAINDICATIONS | Chest pain consistent with angina/cardiac |
| PRECAUTIONS | ■ Protect from light |
| | ■ Assess vital signs every 5 minutes |
| SIDE EFFECTS | ■ Tachycardia |
| | ■ Dizziness |
| | ■ Nausea; vomiting |
| | ■ Headache |
| ROUTE | Intramuscularly (IM) |
| DOSE | 0.3 mg |
| PEDIATRIC DOSE | 0.15 mg for pediatric patient 60 pounds or less |
| ONSET | 5 to 10 minutes |
| DURATION | 20 minutes |
| STOCK | BLS units |
| | (1) Adult Epi-Pen |
| | (1) Epi-Pen Junior |

John Palcheff, DO EMS Medical Director

| | FUROSEMIDE (LASIX) |
|-------------------|--|
| CLASS | Diuretic |
| ACTION | A potent loop diuretic that inhibits sodium and chloride reabsorption at the proximal and distal tubules and ascending loop of Henle in the kidney to promote prompt diuresis. |
| INDICATIONS | Congestive heart failure (CHF) CHF with pulmonary edema |
| CONTRAINDICATIONS | Dehydration Hypotension Hypokalemia Pregnancy Anuria (inability to produce urine) |
| PRECAUTIONS | Protect from light |
| SIDE EFFECTS | Vertigo, restlessness Headache Paresthesia Volume depletion; orthostatic hypotension Blurred vision Nausea; vomiting; anorexia; Hypokalemia, hypochloremic alkalosis; fluid and electrolyte imbalances |
| ROUTE | IV |
| DOSE | 40-80 mg slow IVP over 1-2 minutes |
| PEDIATRIC DOSE | Per Medical Control |
| ONSET | 5 to 10 minutes |
| DURATION | 2 to 3 hours |
| STOCK | (2) 100 mg/10 mL vials |

John Palcheff, DO EMS Medical Director

| | GLUCAGON (GLUCAGEN) |
|-------------------|--|
| CLASS | Endocrine – pancreatic hormone |
| ACTION | Causes breakdown of glycogen stored in the liver to |
| | glucose |
| | Inhibits glycogen synthesis |
| | Elevates blood glucose level |
| INDICATIONS | Hypoglycemia when unable to establish an IV site |
| CONTRAINDICATIONS | Hypersensitivity to the drug |
| | Hypersensitivity to beef or pork protein |
| PRECAUTIONS | Only effective if there are sufficient stores of glycogen in |
| | the liver |
| | Use with caution in patients with cardiovascular or renal |
| | disease |
| | Transport immediately after administration |
| SIDE EFFECTS | Nausea / vomiting |
| ROUTE | IM |
| DOSE | 0.5 - 1 unit (1 unit = 1 mg) |
| PEDIATRIC DOSE | 0.03 mg/kg – maximum dose 1 mg |
| | Utilize Broselow tape or pediatric weight based dosing |
| | chart to confirm dose |
| | Reference policy PED-12.2 |
| ONSET | 5 to 20 minutes |
| DURATION | 20 to 30 minutes |
| STOCK | (1) 1 mg (1 unit) vial; with diluent |

John Palcheff, DO EMS Medical Director

| LIDOCAINE (XYLOCAINE) | | |
|-----------------------|--|--|
| CLASS | | |
| ACTION | Antiarrhythmic Class IB antiarrhythmic agent decreases depolarization | |
| ACTION | the state of the s | |
| | automaticity and excitability in the ventricles during the | |
| | diastolic phase by direct action on the tissues especially the | |
| | Purkinje network. Increases the ventricular fibrillation threshold making it | |
| | mereases the venificatal fibrination threshold making it | |
| | more difficult for the heart to go into VF. | |
| INDICATIONS | Suppresses ventricular ectopic activity Ventricular Tachycardia | |
| INDICATIONS | Ventricular facilycardia Ventricular fibrillation | |
| | Malignant PVCs | |
| CONTRAINDICATIONS | Hypersensitivity to the drug or to the amide-type local | |
| CONTRACTORS | anesthetics. | |
| | High degree heart blocks (2 nd degree type II, 3 rd degree) | |
| | Ventricular ectopy in conjunction with bradycardia | |
| PRECAUTIONS | Monitor level of consciousness for signs of CNS toxicity. | |
| = == + 4 | Consider maintenance infusion after bolus. | |
| | Maintenance infusion dosage should be reduced if over age | |
| | 70, liver disease, CHF or shock. | |
| SIDE EFFECTS | Confusion; lethargy | |
| | Anxiety; restlessness; nervousness | |
| | ■ Lightheadedness | |
| | Muscle twitching; seizures | |
| | ■ Bradycardia | |
| | ■ Hypotension | |
| | Cardiac arrhythmias | |
| | ■ Cardiac arrest | |
| ROUTE | ■ IV push | |
| | Endotracheal (ET) | |
| DOCE | IV infusion | |
| DOSE | 1 to 1.5 mg/kg initial dose. Repeat doses of 0.5 to 0.75 | |
| | mg/kg can be repeated every 5 to 10 minutes to maximum | |
| | of 3 mg. | |
| | Ventricular ectopy: 1 to 1.5 mg/kg IVP; repeat doses every | |
| | 10 minutes at 0.5 to 0.75 mg/kg IVP to maximum of 3 | |
| | mg/kg. Maintenance drip: 2 to 4 mg/minute | |
| PEDIATRIC DOSE | Maintenance drip: 2 to 4 mg/minute 1 mg/kg – may repeat every 3 to 5 minutes to maximum of | |
| | 3 mg | |
| | Utilize Broselow tape or pediatric weight based dosing | |
| | chart to confirm dose | |
| | Reference policy PED-4 | |
| ONSET | 45 to 90 seconds | |
| DURATION | 10 to 20 minutes | |
| STOCK | (3) 100 mg/5 mL Abbojects | |
| | (1) Premix bag 2 grams/500 mL Normal Saline | |
| ···· | - D- D- MAD I TOTALLO CONTROL | |

| MAGNESIUM SULFATE | |
|-------------------|--|
| CLASS | Anticonvulsant; magnesium supplement |
| ACTION | Acts as a physiologic calcium channel blocker to block |
| | neuromuscular transmission. |
| | Central nervous system depressant |
| INDICATIONS | Seizures associated with eclampsia |
| E.DICATIONS | Polymorphic ventricular tachycardia / Torquiag da Painta |
| | Torymorphic ventricular tachycardia / Torsades de Pointe |
| CONTRAINDICATIONS | Ventricular fibrillation associated with hypomagnesemia Heart block |
| Confidential | Hypocalcemia |
| | Hypotension |
| PRECAUTIONS | Side effects can occur from too rapid administration or if |
| | given undiluted. |
| | Monitor vital signs, cardiac status and respiratory status |
| | closely. |
| SIDE EFFECTS | Drowsiness |
| | Depressed reflexes; flaccid paralysis |
| | Respiratory depression; respiratory paralysis |
| | Bradycardia, other arrhythmias |
| | Hypotension; cardiac collapse |
| | Hypothermia |
| | Flushed skin; rash; itching |
| ROUTE | IV |
| DOSE | Seizures associated with eclampsia: 2-4 grams of 50% |
| | solution diluted in 100-250 mL of Normal Saline and |
| | infused over 30 minutes. |
| i | Polymorphic ventricular tachycardia: 1-2 grams of 50% |
| | solution diluted in 10 mL of sterile water and administered |
| | over 1-2 minutes. |
| | Wentricular fibrillation: 1-2 grams of 50% solution IVP |
| PEDIATRIC DOSE | None |
| ONSET | Immediate |
| DURATION | 3 to 4 hours |
| STOCK | (1) 5 grams/10 mL 50% solution Abboject (500 mg/mL) |

| | MORPHINE SULFATE |
|-------------------|---|
| CLASS | Opiate |
| ACTION | Narcotic analgesic that binds to opiate receptors in the brain to produce pain relief. (opiate agonist) Peripheral vasodilation decreases systemic vascular resistance and venous return (decreases preload and afterload) CNS depressant |
| INDICATIONS | ■ Severe pain |
| COMPANIES | CHF with pulmonary edema |
| CONTRAINDICATIONS | History of sensitivity to the drug |
| | ■ Head injury |
| | Hypovolemia |
| | ■ Hypotension |
| - | Undiagnosed abdominal pain |
| PRECAUTIONS | Can cause hypotension and respiratory depression in higher doses. (Narcan should be available as a reversal agent.) |
| SIDE EFFECTS | ■ Decreased level of consciousness |
| | Respiratory depression |
| | ■ Hypotension |
| | Nausea; vomiting |
| | ■ Dizziness |
| | ■ Headache |
| ROUTE | ■ IV |
| | ■ IM |
| DOSE | IV: Standard initial dose is 2 mg. slow IVP. Additional doses may be given upon the order of Medical Control. 2nd dose: 2mg may be given prior to contact Medical Control |
| PEDIATRIC DOSE | Per Medical Control |
| | Utilize Broselow tape or pediatric weight based dosing chart to confirm dose |
| ONSET | ■ IV = Immediate |
| | ■ IM = 5 to 30 minutes |
| DURATION | 3 to 5 hours |
| STOCK | (5) 2 mg/mL tubexes |

| | NALOXONE (NARCAN) |
|-------------------|---|
| CLASS | Narcotic antagonist |
| ACTION | Reverses the effects of narcotics by competing for and blocking opiate receptors. Approved administration by BLS/ALS. |
| INDICATIONS | For complete or partial reversal of narcotics including: morphine, Demerol, heroin, dilaudid, paregoric, percodan, fentanyl, and methadone. For complete or partial reversal of synthetic narcotics such as: nubain, stadol, talwin, Darvon. Coma of unknown origin with suspected narcotic involvement. Alcoholic coma |
| CONTRAINDICATIONS | Known hypersensitivity to the drug |
| PRECAUTIONS | Administer with caution to patients dependent upon narcotics as it may cause withdrawal effects including seizures. Narcan is a short acting drug and the dose may need augmentation every 5 minutes. Larger than average doses (2-5 mg) may be needed for management of Darvon overdose or alcoholic coma. The patient may become combative upon reversal of the opiate. Appropriate precautions should be taken prior to administration to ensure the safety of emergency providers. |
| SIDE EFFECTS | Nausea; vomiting |
| | Tremors |
| | ■ Sweating |
| | ■ Hypertension |
| ROUTE | ■ IV ■ IM ■ Endotracheal (ET) ■ Atomization Device |
| DOSE | 2 mg IVP. May repeat in 2 to 3 minute intervals for 2 to 3 doses if no response. Failure to obtain reversal after 2 to 3 doses indicates other disease process or overdose on other non-opioid type drugs. |
| PEDIATRIC DOSE | Less than 20 kg = 0.1 mg/kg Maximum dose 2 mg Greater than 20 kg = 2 mg single dose Utilize Broselow tape or pediatric weight based dosing chart to confirm dose Reference policy PED-12.2 |
| ONSET | IV = Immediate IM = 5 to 10 minutes |
| DURATION | 20 to 30 minutes |
| STOCK | (1) 10 mL vial (0.4 mg/mL) |

| | NITROGLYCERIN | |
|-------------------|--|--|
| CLASS | Organic nitrate | |
| ACTION | Relaxes vascular smooth muscle | |
| | ■ Dilation of coronary arteries | |
| | Dilation of systemic arteries (reduces afterload) | |
| | Venous dilation (reduces preload) | |
| INDICATIONS | Chest pain suspected to be cardiac in origin | |
| | ■ Pulmonary edema | |
| CONTRAINDICATIONS | Hypotension | |
| PRECAUTIONS | Monitor blood pressure before and after administration of | |
| | each dose. | |
| | ■ Do not administer if systolic BP less than 90 | |
| | ■ Protect from light | |
| SIDE EFFECTS | ■ Headache | |
| | Facial flushing | |
| | ■ Dizziness | |
| | ■ Hypotension | |
| | ■ Bradycardia (rare) | |
| | Reflex tachycardia | |
| ROUTE | Sublingual | |
| | Topical | |
| DOSE | Sublingual: place 1 tablet under the patient's tongue. May | |
| | repeat every 5 minutes for a total of 3 tablets. | |
| | Topical: Used for long transport times when sublingual | |
| | nitroglycerin has been helpful in reducing chest pain. Place | |
| | ½ inch of nitropaste on the ruled applicator measuring | |
| | paper. Apply to a hairless are of the skin on the chest. Tape | |
| | in place. Remove any previously applied nitroglycerin | |
| | patches/ointment. | |
| PEDIATRIC DOSE | None | |
| ONSET | 1 to 2 minutes | |
| DURATION | 15 to 30 minutes | |
| STOCK | (1) 25 tablet bottle of 0.4 mg tablets | |
| | (2) Unit doses of topical nitroglycerin and ruled applicator | |
| | papers | |

| ORAL GLUCOSE (INSTA-GLUCOSE; GLUTOSE) | |
|---------------------------------------|--|
| CLASS | Glucose |
| ACTION | Increases blood glucose levels |
| INDICATIONS | Known or suspected hypoglycemia in the diabetic patient |
| CONTRAINDICATIONS | Decreased level of consciousness that could lead to choking or risk of aspiration. Inability to swallow |
| PRECAUTIONS | None |
| SIDE EFFECTS | None |
| ROUTE | Oral |
| DOSE | 30 grams (one tube) |
| PEDIATRIC DOSE | Only as ordered by Medical Control |
| ONSET | |
| DURATION | |
| STOCK | (1) 30 gram tube |

| | OXYTOCIN (PITOCIN) | |
|-------------------|---|--|
| CLASS | Hormone | |
| ACTION | Stimulates uterine smooth muscle contraction to slow post- | |
| | partum hemorrhage after expulsion of the placenta. | |
| INDICATIONS | Post-partum hemorrhage | |
| CONTRAINDICATIONS | Any condition other than post-partum hemorrhage | |
| PRECAUTIONS | Ensure that the placenta has delivered prior to administration of oxytocin. | |
| | Ensure that there is not another fetus present prior to administration. Too rapid administration could result in uterine rupture. | |
| SIDE EFFECTS | Nausea; vomiting Seizures Hypotension Anaphylaxis Arrhythmias | |
| | ■ Coma | |
| ROUTE | IM IV infusion | |
| DOSE | IM: 3-10 units IV infusion: Mix 10 units in 1000 mL of Normal Saline. This yields 10 milliunits/mL. Start the infusion very slowly at 10 milliunits (1mL) per minute or as indicated by Medical control. | |
| PEDIATRIC DOSE | None | |
| ONSET | IV = Immediate IM = 3 to 5 minutes | |
| DURATION | IV = 20 minutes after infusion is stopped IM = 2 to 3 hours | |
| STOCK | (1) 10 USP units/mL vial | |

| J | PROMETHAZINE (PHENERGAN) |
|-------------------|---|
| CLASS | Phenothiazine Antihistamine |
| ACTION | Inhibits the chemoreceptor trigger zone in the medulla to produce |
| | anti-emetic effect. Blocks H1 and H2 histamine receptor sites. |
| INDICATIONS | Vomiting |
| CONTRAINDICATIONS | Acute asthma attack |
| PRECAUTIONS | Extravasation (infiltration) can cause necrosis, tissue sloughing, gangrene Should be diluted in at least 10 mL Normal Saline Should be administered very slowly over several minutes Patient should be instructed to advise you if any pain or burning with administration |
| SIDE EFFECTS | Drowsiness; excess sedation; confusion Hypotension Dizziness |
| | Palpitations |
| ROUTE | IV |
| DOSE | 12.5 mg diluted in 10 mL Normal Saline slow IVP. May repeat X 1 if necessary for a maximum dose of 25 mg. |
| PEDIATRIC DOSE | Child over age 2 = 0.25 - 0.5 mg/kg with maximum dose of 25 mg Not for administration in patients under the age of two years. Dilute in 10 mL normal saline and administer very slowly over several minutes Utilize Broselow tape or pediatric weight based dosing chart to confirm dose |
| ONSET | 3 to 5 minutes |
| DURATION | 6 to 12 hours |
| STOCK | (2) 25 mg inj. |

| | SODIUM BICARBONATE | |
|-------------------|--|--|
| CLASS | Alkalinizing agent (buffer) | |
| ACTION | Binds free hydrogen ions to form carbonic acid. Effectively | |
| | increases the blood pH. | |
| INDICATIONS | Acidosis associated with prolonged down time in cardiac | |
| | arrest | |
| | Tricyclic antidepressant overdose | |
| CONTRAINDICATIONS | Alkalosis | |
| PRECAUTIONS | Correct dosage is essential to avoid overcompensation of pH. | |
| | Flush IV line before and after administration of the drug. Is | |
| | not compatible with many other drugs in the IV line. | |
| | Precipitates with calcium chloride. Inactivates epinephrine | |
| | and dopamine. | |
| | Extravasation (infiltration) may cause ulceration, tissue | |
| | necrosis or tissue sloughing at injection site. | |
| SIDE EFFECTS | Alkalosis | |
| | Electrolyte imbalance | |
| ROUTE | IV | |
| DOSE | 1 mEq/kg initially followed by 0.5 mEq/kg every 10 minutes. | |
| PEDIATRIC DOSE | Use pediatric 4.2% solution. | |
| | 0.5-1 mEq/kg initial dose followed by 0.5 mEq/kg doses | |
| | every 10 minutes as indicated. | |
| | Utilize Broselow tape or pediatric weight based dosing | |
| | chart to confirm dose | |
| ONSET | Immediate | |
| DURATION | 30 to 60 minutes | |
| STOCK | (1) 50 mL Abboject (1 mEq/mL) | |
| | (2) (1) 10 mL Abboject 4.2% pediatric solution (0.5 | |
| | mEq/mL) | |

| VERAPAMIL (CALAN) | |
|-------------------|--|
| CLASS | Calcium channel blocker |
| ACTION | Blocks the entry of calcium into the cell |
| | Slows conduction through the AV node |
| | Negative chronotrope (slows heart rate) |
| | Negative inotrope (decreased force of cardiac contraction) |
| INDICATIONS | To control the rate in hemodynamically stable atrial fibrillation or |
| | atrial flutter with rapid ventricular response. |
| CONTRAINDICATIONS | M Hypotension |
| | Cardiogenic shock |
| | Myocardial infarction |
| | ■ Wide complex tachycardias |
| | ■ WPW syndrome |
| | Patients taking beta blockers |
| PRECAUTIONS | Vital signs should be monitored closely. |
| | May induce or exacerbate CHF/pulmonary edema |
| SIDE EFFECTS | ■ Headache |
| | Dizziness |
| | ■ Sweating |
| | ■ Seizures |
| | ■ Bradycardia |
| | Heart blocks |
| | ■ Hypotension |
| | Asystole |
| | ■ Ventricular fibrillation |
| ROUTE | IV |
| DOSE | ■ 2.5-5 mg slow IVP over 2-3 minutes. |
| | May repeat at 5-10 mg in 15-30 minutes if rhythm persists |
| | with no adverse effects after initial dose. |
| | ■ Total dose should not exceed 30 mg in 30 minutes. |
| PEDIATRIC DOSE | Verapamil is not recommended in the pediatric population |
| | in the absence of Medical Direction. |
| | Reference policy PED-5 |
| ONSET | 3 to 5 minutes |
| DURATION | 2 hours |
| STOCK | (2) 5 mg/2 mL vials |

| METOPROLOL TARTRATE | | |
|---------------------|--|--|
| CLASS | Beta-Adrenergic blocking agent | |
| ACTION | Exerts mainly beta-1 adrenergic blocking activity although Beta-2 receptors are blocked at high doses | |
| INDICATIONS | Acute MI in hemodynamically stable patients | |
| CONTRAINDICATIONS | MI in patients with a HR of less than 60 bpm | |
| | ■ 2 nd or 3 rd degree heart blocks | |
| | Systolic BP is less than 100 | |
| | Sinus Bradycardia | |
| PRECAUTIONS | Use with caution in impaired hepatic function and during lactation | |
| SIDE EFFECTS | z | |
| ROUTE | m PO | |
| DOSE | ■ 25 mg | |
| PEDIATRIC DOSE | ■ Not determined for children | |
| ONSET | 15 minutes | |
| DURATION | | |
| STOCK | 25 mg tablet | |

Jersey Community Hospital, EMS Medical Director

| PLAVIX | |
|-------------------|--|
| CLASS | Anitplatelet drug |
| ACTION | works by preventing a natural substance called ADP from binding to its receptors on platelets ADP is one of the chemicals in the body that cause platelets to clump together. |
| INDICATIONS | Reduction of MI, Stroke and Vascular death in patients with atherosclerosis. |
| CONTRAINDICATIONS | ■ Lactation ■ Active bleeding such as peptic ulcer or intracranial hemorrhage |
| PRECAUTIONS | Use with caution in those at risk of increased bleeding from trauma, surgery or other pathological conditions |
| SIDE EFFECTS | Edema Hypertension Intracranial hemorrhage |
| ROUTE | s PO |
| DOSE | 300 mg PO unless patient is older than 75 yrs and will be getting thrombolytics then dose is 75 mg. |
| PEDIATRIC DOSE | Not determined for children |
| ONSET | |
| DURATION | |
| STOCK | 75 mg tablets x 4 |

| | VERSED (MIDAZOLAM) | |
|----------------------------------|---|--|
| Versed 10 mg/2ml, 5 mg/1ml vials | | |
| CLASS | Benzodiazapine | |
| ACTION | Short acting benzodiazepine that works as a central nervous system depressant. It is 3-4 times more potent than Valium. | |
| INDICATIONS | Indicated for use in status epilepticus, pre-procedural sedation, severe anxiety, as an amnesic, and as an aid to anesthesia and intubation. | |
| CONTRAINDICATIONS | Known hypersensitivity to the drug, or any of its components (propylene glycol). Patients with narrow angle glaucoma. Pregnancy category D. | |
| PRECAUTIONS | | |
| SIDE EFFECTS | As with all benzodiazepines, paradoxical reactions such as stimulation, mania, restlessness, agitation, aggression, psychosis, and hallucinations may occur. | |
| ROUTE | X . | |
| DOSE | ■ Adult: Given as 2-5 mg doses IV/IM | |
| PEDIATRIC DOSE | Pediatric: 0.05-0.1 mg/kg IV or 0.1-0.15 mg/kg IM | |
| ONSET | | |
| DURATION | See SPECIAL CONSIDERATIONS below | |
| STOCK | 4 (5 mg / 5 ml vial) | |
| SPECIAL | Observe for signs of respiratory depression. Use with caution | |
| CONSIDERATIONS | in patients who are hypotensive. Versed should be given in | |
| | small titratable doses over 2 minutes, with an additional 2 | |
| | minutes of observation for maximal effect before additional | |
| | doses are given. All patients should have monitoring | |
| | equipment in place prior to administration, and equipment should be readily available to intubate, resuscitate the patient | |
| | as necessary. | |

| NORCURON | | |
|--|---|--|
| 10 mg/10ml reconstituted (Vecuronium Bromide): | | |
| CLASS | Nondepolarizing skeletal muscle relaxant | |
| ACTION | A non-depolarizing skeletal muscle relaxant of intermediate onset and duration. It can be used for maintenance of neuromuscular block. Acceptable intubating conditions can be achieved in approximately 3 minutes. Elimination is primarily through hepatic mechanisms with a half-life of approximately 70 minutes and duration of 30-60 minutes. Has minimal effects on hemodynamics and causes little or no histamine release. | |
| INDICATIONS | Maintenance of neuromuscular blockade in intubated and ventilated patients. Neuromuscular blockade during rapid sequence intubation when succinylcholine is contraindicated. | |
| CONTRAINDICATIONS | Hypersensitivity to drug. Pregnant and lactating women | |
| PRECAUTIONS | | |
| SIDE EFFECTS | Flaccid paralysis, respiratory depression | |
| ROUTE | 8 | |
| DOSE | Adult: 0.1 mg/kg IV bolus (10 mg max dose) | |
| PEDIATRIC DOSE | Pediatric -0.1 mg/kg IV bolus (10 mg max dose) | |
| ONSET | | |
| DURATION | = 25-30 minutes | |
| STOCK | ■ 20 mg vial | |
| SPECIAL CONSIDERATIONS | Prolonged recovery time in patients with liver disease. Burn patients may require higher doses due to resistance to non-depolarizing agents in this population. Pediatric patients, age 1-10 years of age may require a slightly higher initial dose and more frequent re-dosing. Pediatric patients under age 1 year are more sensitive to the medication and may take 1 1/2 times longer to recover. | |

| ONDANSETRON | | |
|---------------------------|--|--|
| (ZOFRAN): | | |
| CLASS | Anti-emetic, selective Sero | otonin (5HT3) Receptor antagonist |
| ACTION | which activates the oblongata, and also | es the activity of the vagus nerve vomiting center in the medulla blocks serotonin receptors in the ger zone. It has little effect on motion sickness. |
| INDICATIONS | Moderate to severe | nausea, vomiting |
| CONTRAINDICATIONS | Hypersensitivity to the prolonged QT syndromal Concurrent use of Apparkasonian drug | |
| PRECAUTIONS | Use with caution wit which effect AT inte TCA's, Haldol)Use with caution wit | hildren less than 2 years of age h patients concurrently using drugs rval (i.e., Procainamide, amiodarone, h hepatic impairment (consider ttervals or decreasing dose) |
| SIDE EFFECTS | SedationHypotensionTachycardia | AnginaTorsades de Pointes (rare)Constipation |
| ROUTE | IV/IO | - Consuportion |
| DOSE (ADULT) | | l once in 15 minutes PRN |
| PEDIATRIC DOSE | | f age) Contact Medical Control |
| ONSET | 3–5 minutes | |
| DURATION | ■ 2-4 hours | |
| STOCK | ■ 4 mg/2 ml vials | |
| SPECIAL CONSIDERATIONS | | |

| FENTANYL CITRATE (SUBLIMAZE) | |
|------------------------------|--|
| CLASS | Opiate; synthetic narcotic |
| ACTION | A potent, short-acting opioid agonist; Relieves pain by stimulating |
| | receptors in the central nervous system. It has an analgesic effect |
| | approximately 50-100 times greater than that of morphine - a 50 mcg |
| | dose has roughly the same analgesic effect as 5 mg of morphine. |
| INDICATIONS | Non-cardiogenic pain |
| | Cardiogenic pain |
| | Aid in procedural sedation |
| CONTRAINDICATIONS | Hypersensitivity to the drug |
| PRECAUTIONS | Has an additive effect with other opiates and benzodiazepines / sedatives |
| | including alcohol which may contribute to respiratory depression. |
| | Rapid administration may result in spasm of respiratory muscles and |
| | chest wall rigidity resulting in difficulty or inability to ventilate the patient. |
| | Administer slowly to prevent this complication. |
| SIDE EFFECTS | CNS depression, respiratory depression, bradycardia, transient |
| | hypotension, ventilatory impairment in COPD patients, hives |
| ROUTE | IV |
| DOSE | Adult: 25 mcg slow IVP; may repeat dose prior to calling Medical Control |
| PEDIATRIC DOSE | Requires contact with Medical Control |
| | 0.1 mcg/kg slow IVP |
| ONSET OF ACTION | Immediate for IV route |
| DURATION OF ACTION | Peak effect 30-60 minutes |
| STOCK | 2 100mcg/2ml bottles |
| NOTE: | Fentanyl Citrate should be mixed with 10ml of Normal saline flush prior to |
| | administration |

IV FLUIDS

| 0.9% SODIUM CHLORIDE (NORMAL SALINE) | | |
|--------------------------------------|--|--|
| CLASS | | |
| ACTION | Fluid and sodium replacement | |
| INDICATIONS | Heat-related problems (e.g., heat exhaustion, heat stroke) Freshwater drowning Hypovolemia Diabetic ketoacidosis IV Lifeline | |
| CONTRAINDICATIONS | • None | |
| PRECAUTIONS | Electrolyte depletion (K+, Mg++, Ca++, among others) can occur following administration of large amounts of normal saline May cause fluid overload if rate is not closely monitored. | |
| SIDE EFFECTS | ■ Thirst | |
| ROUTE | IV Infusion | |
| DOSE | Dependent upon patient condition and situation being treated. In freshwater drowning and heat emergencies, the administration is usually rapid | |
| PEDIATRIC DOSE | Dose is dependent on patient size and condition Trauma resuscitation 20 ml/kg initial bolus Utilize Broselow Tape or pediatric weight based dosing chart to confirm dose. Reference Policy PED-9 | |
| ONSET | | |
| DURATION | | |
| STOCK | | |

| RECTAL DIAZEPAM (VALIUM) | | |
|--------------------------|---|--|
| CLASS | Benzodiazepine | |
| - | Anti convulsant; skeletal muscle relaxant, sedative-hypnotic | |
| ACTION | Anticonvulsant properties due to enhancement of GABA-mediated | |
| 1101101 | presynaptic inhibition at the spinal level as well as in the brain stem | |
| | reticular formation. CNS depressant. | |
| INDICATIONS | Active seizures | |
| A DICHTIONS | Sedation prior to synchronized cardioversion | |
| | Sedation prior to synchronized cardioversion Sedation prior to transcutaneous pacing | |
| | Acute anxiety | |
| | In the emergency setting you may give diazepam rectally if | |
| | you cannot establish an intravenous line. Rectal | |
| | administration may prove advantageous with the | |
| | unconscious or pediatric patient or when IV access is | |
| | impractical or not possible. | |
| CONTRAINDICATIONS | History of hypersensitivity to the drug | |
| PRECAUTIONS | | |
| FRECAULIONS | May precipitate if mixed with other drugs – always flush the IV line before and after administration. | |
| | | |
| | Executy patients may experience adverse effects more | |
| | quickly – administer the medication slowly. | |
| | Monitor level of consciousness, BP, pulse and respiratory | |
| | status closely | |
| CINE PERIODO | Be prepared to manage the airway | |
| SIDE EFFECTS | CNS depression; drowsiness | |
| | Respiratory depression | |
| | Hypotension | |
| DOLLAR | Phlebitis; venous thrombosis | |
| ROUTE | IV (administer no faster than 1 mg/minute) | |
| | IM (Onset of action 15-30 minutes) | |
| D.C.C. | Rectal | |
| DOSE | Seizures: 5-10 mg slow IV push at 1 mg/minute. Maximum | |
| | dose of 10 mg. | |
| | Sedation prior to electrical therapy: 5-10 mg slow IV push | |
| | at 1 mg/minute. Maximum dose of 10 mg. | |
| | Acute anxiety: 2-5 mg IM or slow IV push. | |
| PEDIATRIC DOSE | For Seizures: 0.1-0.3 mg/kg slow IV push over 2-3 | |
| | minutes. | |
| | Less than age 5 maximum dose = 5 mg | |
| | Over age 5 maximum dose 10 mg | |
| • | Utilize Broselow tape or pediatric weight based dosing | |
| | chart to confirm dose. | |
| | Reference policy PED-11.2 | |
| ONSET | IV = less than 15 minutes | |
| | IM = 15 to 30 minutes | |
| DURATION | 3 hours | |
| STOCK | (2) 10 mg/2 mL syringes | |
| | | |

Note: Compute dosage. Confirm the indication of administration and dose. Remove the needle from the TB syringe for children or the 3mL syringe for adults. Pull plunger back to the desired amount. Insert the diazepam needles into the hub (the part the needle connects with) of the TB or 3mL syringe. Inject the desired amount of diazepam into the appropriate syringe(s) e.g. an older child may exceed greater than the 1 mL TB syringe

can hold, a second TB syringe may be required to accurately measure a dose of greater then 1mL. Lubricate the tip of the syringe to be used for rectal administration. Insert the syringe without the needle into the rectum. [Note: a 3-5 mL syringe may be used for dosage greater than 1 mL that a tuberculin syringe allows. It is acceptable in this circumstance to attach an over the needle catheter (plastic portion only) and lubricate the catheter prior to rectal insertion. Administration of diazepam too high into the rectum may decrease its anticonvulsant effect, because the drug may be absorbed differently and broken down more quickly in the liver.] Push the plunger to expel the diazepam into the rectum. Withdraw the catheter and hold the patient's buttocks together thus permitting retention and absorption.

John Palcheff, DO EMS Medical Director